The Latest Cardiac and Vascular News
WARRINGTON, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the Company’s Board of Directors has approved a 1-for-50 reverse stock split of its issued and outstanding common […]
Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE) Submitted IND application for NTLA-2002 to enable patient enrollment in the U.S. for the Phase 2 study Plans to submit IND application in mid-2023 for global pivotal study of NTLA-2001 for the treatment […]
Allows Endovascular Procedure to be Performed from the Cath-Lab Control Room, Potentially Minimizing Radiation Exposure and Reducing Physical Strain for the Healthcare Providers Design Patent Complements Existing U.S. and European Design Patents as Feedback During Recent Meetings Continues to Support a Positive User Experience HINGHAM, Mass., Feb. 23, 2023 (GLOBE […]
–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30 topline registrational data are expected to be announced in mid-2023 –Phase 2 PROPEL 2 trial of low-dose infigratinib as a potential treatment option for children with achondroplasia continues to progress […]
Gradual resumption in Aeson® implantations in line with progressive production ramp-up over the year 2023 Cash position of €51 million as of December 31, 2022 and active exploration of financing options to extend cash runway beyond July 2023 Confirmation of a sales target of €10 to €13 million in 2023 CARMAT […]
LUND, Sweden, Feb. 22, 2023 /PRNewswire/ — Syntach AB (“Syntach”) is pleased to announce that the Company’s Syntach Cardiac Support system (Syntach CS) has been selected for an oral presentation in the Best Innovation Competition to be held during the CRT 2023 annual meeting taking place at the Omni Shoreham Hotel in Washington […]
A PRIORI study to evaluate safety and performance of novel Aortix percutaneous mechanical circulatory support device to increase renal perfusion Study adds to the growing body of data for the Aortix pump, which will be featured in a late-breaking presentation at the Technology and Heart Failure Therapeutics conference in March HOUSTON, Feb. […]
The study will assess the role of Huawei’s wearable technology to detect atrial fibrillation in post-stroke patients OXFORD, England, Feb. 22, 2023 /PRNewswire/ — Brainomix has announced its involvement in a new study sponsored by the University of Liverpool focused on post-stroke atrial fibrillation (AF). Sites with existing clinical deployments of Brainomix’s e-Stroke platform will […]
Eplontersen NDA submitted to FDA; tofersen under regulatory review for marketing approval in U.S. and EU Phase 3 data planned for eplontersen and olezarsen; robust late-stage pipeline expanding with two new Phase 3 programs Ionis provides full year 2023 financial guidance CARLSBAD, Calif., Feb. 22, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) […]
ROCKVILLE, Md., Feb. 22, 2023 /PRNewswire/ — An expert consensus statement published today by the Heart Failure Society of America (HFSA) offers best practices in the management of patients on durable Mechanical Circulatory Support (MCS), focusing on pharmacological therapies administered to patients on continuous flow Left Ventricular Assist Devices (LVADs). “Over the […]
